Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | -435.00 | 18.32K | 595.08K | 879.78K | 573.12K | 907.58K |
Gross Profit | -558.91K | -301.45K | 281.80K | 612.64K | 399.92K | 640.45K |
EBITDA | -2.41M | -2.97M | -3.14M | -2.92M | -2.39M | -2.05M |
Net Income | -2.36M | -2.41M | -3.10M | -2.80M | -2.36M | -1.87M |
Balance Sheet | ||||||
Total Assets | 1.87M | 3.16M | 3.84M | 7.30M | 5.00M | 6.57M |
Cash, Cash Equivalents and Short-Term Investments | 1.34M | 2.21M | 2.99M | 6.34M | 3.93M | 5.52M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.66K |
Total Liabilities | 541.70K | 368.45K | 613.88K | 1.03M | 754.57K | 567.29K |
Stockholders Equity | 1.33M | 2.79M | 3.22M | 6.27M | 4.25M | 6.00M |
Cash Flow | ||||||
Free Cash Flow | -1.88M | -2.76M | -3.28M | 36.67K | -1.83M | -1.64M |
Operating Cash Flow | -1.88M | -2.75M | -3.28M | 43.52K | -1.83M | -1.64M |
Investing Cash Flow | 0.00 | -5.70K | 0.00 | -6.84K | -3.03K | 0.00 |
Financing Cash Flow | 0.00 | 1.98M | -75.00K | 4.41M | 239.88K | 2.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $1.17B | 70.51 | 9.23% | ― | 10.79% | 5.20% | |
69 Neutral | $8.19B | 160.20 | 14.52% | ― | 55.85% | 893.42% | |
49 Neutral | AU$123.92M | ― | -35.20% | ― | 4.68% | -155.42% | |
49 Neutral | AU$2.50B | 4.42 | -64.25% | 2.77% | 36.51% | 13.14% | |
42 Neutral | AU$5.06M | ― | ― | ― | ― | ||
40 Underperform | $93.34M | ― | -99.05% | ― | ― | -33.99% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
Bio-Gene Technology Ltd announced a correction to a previous statement regarding the proposed issue of securities. This update, which addresses a typographic error, pertains to the company’s plans to offer securities under a securities purchase plan. The correction ensures clarity in the company’s communication with stakeholders and aligns with ASX listing rules, potentially impacting investor confidence and market positioning.
Bio-Gene Technology Ltd has announced a proposed issue of securities, including unlisted options and ordinary fully paid shares, as part of a securities purchase plan and placement. This move is expected to enhance the company’s financial position, potentially enabling further development of its insecticide products and strengthening its market presence.
Bio-Gene Technology Ltd. presented an investor update highlighting its progress in developing nature-derived insecticides. This initiative is expected to enhance the company’s market positioning by offering sustainable solutions to pest control, potentially impacting stakeholders positively by addressing global insecticide needs.
Bio-Gene Technology Ltd announced a successful capital raise of $2.1 million through a placement with sophisticated investors and plans to offer a Share Purchase Plan to eligible shareholders. The funds will be used to conduct regulatory-enabling safety studies for Flavocide®, a key step towards its approval in Australia, and to support the scale-up of Qcide, product development, and strategic projects. This financial boost is expected to significantly advance Bio-Gene’s operational capabilities and strengthen its position in the pest control industry.
Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides. This presentation highlights Bio-Gene’s commitment to addressing insecticide resistance and toxicity issues, potentially enhancing its market position and offering stakeholders innovative solutions for pest management.
Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Tim Grogan will present on the company’s innovative insecticide solutions. This presentation highlights Bio-Gene’s commitment to addressing pest control challenges and could enhance its visibility and positioning in the bio-insecticide industry, potentially impacting stakeholders by showcasing its environmentally friendly and effective products.
Bio-Gene Technology Limited reported several key achievements for the six months ending December 2024, including a collaboration with Envu to develop Flavocide® for mosquito management, successful pilot-scale production of Flavocide, and the initiation of safety studies in Europe and India. The company also completed its thirteenth Qcide® harvest, improved seed and seedling production, and expanded formulation development programs. Additionally, Bio-Gene strengthened its intellectual property portfolio with six new patents and five new applications, positioning itself strongly in the bio-insecticide market.